Episode 215 - Gary Forbes, T1D Author, Former Pro Basketball Player

This episode is sponsored by Gvoke HypoPen® (glucagon injection). Gvoke HypoPen® is an emergency glucagon for very low blood sugar in a convenient auto injector that is available in 2 pre-measured doses for adults and children.  Note from Rob: I have partnered with Gvoke® before, and I’ve been working with Xeris Pharmaceuticals® since 2018 - I even interviewed their CEO back in March 2020. If you want to hear that interview with Xeris President & CEO, Paul Edick, from March 2020, check out episode 143 of Diabetics Doing Things.  I’m also really careful not to promote products that I don’t personally use and I have used  Gvoke HypoPen® for very low blood sugar before. I’ve told the story on this podcast before and I am convinced that if you are on insulin, you should have emergency glucagon around, just in case of a very low blood sugar, and I use Gvoke HypoPen®. Gvoke shouldn’t be used in patients with pheochromocytoma or insulinoma – visit gvokeglucagon.com/risk. I also want to address that I will not promote pharmaceutical products without the opportunity to promote patient assistance programs because if my listeners can’t access glucagon, how can they use it to treat their very low blood sugar? So, if you visit the savings and support tab on GvokeGlucagon.com, you can get a $25 coupon for patients on commercial insurance plans, and there is a contact form to fill out for people not on commercial plans.  Now onto the show: Gary Forbes is back on the pod! In this episode, Gary and Rob talk about: * The transition from professional basketball player to author * Being the most recent player in the NBA with T1D * The Sole Survivors , a comic series about heroes with chronic illnesses * The superpower of words and attitude * His father, an Olympic athlete living with diabetes * Playing with Team Defeat Diabetes For more details and important safety information, visit GvokeGlucagon.com . 

There are no comments yet.

Please log in to write the first comment.